BioCryst Pharmaceuticals Secures $69 Million Influenza Contract
BioCryst Pharmaceuticals Announced Major Contract for RAPIVAB
RESEARCH TRIANGLE PARK, N.C. — BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), a leader in the biotechnology sector, has secured a significant contract from the U.S. Department of Health and Human Services (HHS). This award, worth up to $69 million, is designated for the procurement of RAPIVAB® (peramivir injection), a critical medication for treating influenza. The deal enables the purchase of approximately 95,625 doses over the span of five years, highlighting the government's commitment to public health and preparedness.
Details of the Influenza Contract
The contract, facilitated through the Office of the Administration for Strategic Preparedness and Response (ASPR), aims to bolster the Strategic National Stockpile (SNS). This is crucial as the SNS serves as the primary reserve of essential pharmaceuticals and medical supplies poised for use during public health emergencies.
The structure of the contract includes a base ordering period lasting 12 months, with the option for the government to renew for four additional annual ordering periods. Recently, ASPR opted for the first ordering period, committing $13.9 million for the initial supply. BioCryst plans to provide 19,125 doses as part of this phase, delivering them steadily up until September 29, 2025.
Importance of RAPIVAB in Public Health
Dr. Helen Thackray, BioCryst's chief research and development officer, emphasized the significance of RAPIVAB in the U.S. government’s ongoing influenza preparedness strategy. She stated, "Since the 2009 H1N1 pandemic, RAPIVAB has been an important component of our efforts. Given the new mutations in circulating influenza viruses, ensuring RAPIVAB is readily available remains paramount for addressing potential outbreaks." This proactive approach aims to equip health services with effective treatments as influenza continues to evolve.
A Historical Perspective on RAPIVAB
RAPIVAB was first included in the government’s stockpile during the emergency use authorization established in 2009 in response to the H1N1 influenza pandemic. In a further commitment to enhancing public health, the Centers for Disease Control and Prevention awarded BioCryst a $34.7 million contract in 2018 for an additional procurement of RAPIVAB doses. By 2022, this contract was successfully fulfilled, demonstrating BioCryst's capacity to respond to governmental health needs.
Understanding RAPIVAB (peramivir injection)
RAPIVAB® (peramivir injection) is an FDA-approved treatment for patients aged six months and older, offering quick relief for acute, uncomplicated influenza symptoms, provided these symptoms have been present for no longer than 48 hours. The medication is delivered via intravenous infusion, facilitating a swift response when timing is crucial in dealing with influenza.
Administering RAPIVAB requires a minimum of 15 minutes, with recommended doses of 600 mg for adults and adolescents and 12 mg/kg for children aged six months to 12 years. Clinical trials demonstrating the efficacy of RAPIVAB focused mainly on influenza A virus, with some trials including patients affected by influenza B virus.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is committed to developing therapies that improve the lives of individuals affected by complement-mediated and rare diseases. Capitalizing on its expertise in structure-guided drug design, BioCryst is advancing innovative first-in-class and best-in-class therapeutics. Among its notable products is ORLADEYO® (berotralstat), a leading oral plasma kallikrein inhibitor that has gained significant attention in the treatment landscape.
To discover more about BioCryst's initiatives and products, stakeholders are encouraged to visit their official website or follow their updates on professional platforms.
Frequently Asked Questions
What is RAPIVAB used for?
RAPIVAB is primarily used for the treatment of acute uncomplicated influenza in patients aged six months and older.
How much has BioCryst been awarded in this contract?
BioCryst Pharmaceuticals has been awarded up to $69 million for the procurement of RAPIVAB.
What is the role of the Strategic National Stockpile?
The Strategic National Stockpile is the U.S. government's repository of medical supplies and pharmaceuticals for emergency response during health crises.
Who oversees the contract awarded to BioCryst?
The contract was awarded by the U.S. Department of Health and Human Services, specifically through the Office of the Administration for Strategic Preparedness and Response.
When will the doses be supplied?
The initial supply of 19,125 doses is scheduled to be fulfilled between now and September 29, 2025.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Apono Secures $15.5 Million to Innovate Cloud Access Security
- Clene Inc. Raises $7.3 Million for Neurodegenerative Research
- My Density Matters Secures Grant to Enhance Breast Cancer Awareness
- Steakholder Foods Secures Purchase Order, Marking Revenue Milestone
- Empowering Growth: White Oak’s $120 Million Credit Facility
- Neeve's $15 Million Investment Enhances Smart Building Technology
- Madrigal Pharmaceuticals Paves New Paths in NASH Treatment
- GRI Bio Secures Japan Patent, Paving Way for Innovative Treatments
- Alnylam Pharmaceuticals Sees Bright Future Amid Strong Data Boost
- Clene Inc. Secures $7.3 Million Through Direct Stock Offerings
Recent Articles
- Gain Therapeutics Shares Promising Phase 1 Data on GT-02287
- Hydreight Technologies Unveils Share Buyback Initiative
- Vor Bio Welcomes Dr. Han Choi as Chief Financial Officer
- Key Leadership Appointment at Silvaco Enhances Legal Expertise
- Onity Group's Strategic Moves to Restructure Capital for Growth
- West Red Lake Gold Emphasizes Commitment to Reconciliation
- Alamos Gold Announces Upcoming Conference for Q3 2024 Results
- Wabash Hosts Ignite 2024: Innovating the Future of Logistics
- Fanhua Announces Upcoming Extraordinary General Meeting Details
- Auddia Expands faidr App with Over 13,000 AM/FM Stations
- AECOM Welcomes Jill Hudkins as Head of Water Advisory Line
- Baladna Expands Influence with New Dairy Production Projects
- Diversified Healthcare Trust Sells Senior Living Communities for $135M
- Kubicle Partners with Rand Mutual Assurance for Digital Growth
- Tech Stocks Poised for Growth Amid Economic Uncertainty
- Verizon and Vertical Bridge Discuss Major Tower Sale Agreement
- Future Growth of the Solvents Market and Key Insights Ahead
- Strong Recovery in Global Equity Fund Inflows Amid Changes
- TE Connectivity's Strategic Move to Incorporate in Ireland
- Positive Outlook for Elanco as Zenrelia Gains Traction in Market
- Expedited Cash Advances for Lawsuit Plaintiffs in Utah
- Truist Keeps Positive Outlook on Evolent Health Stock Amid Changes
- Albemarle Corporation Announces Q3 2024 Earnings Release
- Barclays Adjusts Procter & Gamble Rating Amid Global Pressures
- Vestis Sells Minority Stake for $37 Million to Boost Agility
- KalVista Advances Novel Oral HAE Treatment for Global Approval
- Potential Sales Surge for Travere Therapeutics Stock Forecasted
- Guggenheim Optimistic on Apogee's Potential in Th2 Market
- Market Trends: Nifty 50 and BSE Sensex Face Setbacks
- Impending Solar Tariffs: A Double-Edged Sword for America
- US and Global Markets Outlook: What to Expect in Q4
- Cypher Capital Invests in $12 Million SecondLive Funding Round
- AT&T's Major Shift: Exiting DirecTV Stake for $7.6 Billion
- Exploring Top Dividend Stocks for Consistent Returns
- European Auto Sector Faces Challenges Amid Economic Uncertainty
- The Future of Eco-Friendly Packaging in a Growing Market
- Suncare Sector Set for USD 18.5 Billion Growth by 2032
- Sustainable Growth in Tetrahydrofuran Market Projected
- Elon Musk and Paul Graham Clash Over Twitter's Transformation
- Mitchell Companies Revolutionizes Beverage Distribution Strategy
- Forecast: Global Veterinary Arthroscopy Device Market Boom
- Radisson Mining Resources to Raise $3 Million in Funding
- Greentone and Sollum Technologies Unite to Innovate Cultivation
- Wesdome Gold Mines Welcomes Guy Belleau as COO
- Advanced Cooling Technologies Secures Funding for Innovative Data Solutions
- Bistro Napa Achieves AAA Four Diamond Honor at Atlantis
- EUMETSAT Conference Unites Experts for Climate Insights
- Emeren Group's Solar Project Sale Boosts Growth in Europe
- Revolutionary Insights for Targeting Cancer: Indivumed's Findings
- How reAlpha's Investment in Xmore AI Enhances Cybersecurity